SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TMCI reported Third Quarter 2026 results. The price and volatility reaction is pending.
TMCIearnings

Treace Medical Concepts, Inc. (TMCI) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Third quarter 2026 revenue was $48.3 million, a 4% decrease compared to $50.2 million in the third quarter of 2025.
  • Third quarter 2026 net loss was $(12.6) million, or $(0.19) per share, compared to $(16.3) million, or $(0.26) per share, in the third quarter of 2025.
  • Third quarter 2026 Adjusted EBITDA was $0.3 million, compared to $(2.6) million in the third quarter of 2025.
  • Gross profit for the third quarter of 2026 was $38.4 million, with gross margin of 79.5%.
  • Total operating expenses decreased 10% to $49.9 million in the third quarter of 2026 compared to $55.4 million in the third quarter of 2025.
  • Cash, cash equivalents, and marketable securities totaled $39.8 million as of September 30, 2026.

Guidance

  • Full-year 2026 revenue guidance is updated to be in the range of $206 million to $210 million.
  • Full-year 2026 Adjusted EBITDA loss is expected to be in the range of $1.0 million to $2.0 million.
  • Reiterated expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →